Premium
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis‐chloroethyl nitrosourea in colon cancer
Author(s) -
Falkson Geoffrey,
Van Eden Errol B.,
Falkson Hendré C.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197405)33:5<1207::aid-cncr2820330502>3.0.co;2-9
Subject(s) - medicine , vincristine , nitrosourea , vomiting , gastroenterology , nausea , fluorouracil , lomustine , progressive disease , surgery , cyclophosphamide , chemotherapy
A randomized clinical trial was undertaken comparing A) fluorouracil (FU) 15 mg/kg/day I.V. X 5 given monthly; and B) fluorouracil 10 mg/kg/day I.V. on day 1 to 5; imidazole‐4‐carboxamide, 5‐(3,3‐dimethyl‐1‐triazeno) (ICDT) 3 mg/ kg/day I.V. on days 1 and 2; vincristine (VCR) 0.025 mg/kg I.V. on day 1; and 1,3‐bis‐(2‐chloroethyl)‐1‐nitrosourea (BCNU) 1.5 mg/kg I.V. on day 1. Of 24 patients in Group A (FU), the response seen was complete remission in 2, partial remission in 4, improvement in 3, no change in 4, and progressive disease in 11. Of 28 patients randomized to Group B (FU, ICDT, VCR, and BCNU) the response seen was complete remission in 4, partial remission in 8, improvement in 4, no change in 2, and progressive disease in 10. The worthwhile response rate in patients receiving FU was therefore 25%, while that in the group receiving the four‐drug combination was 42.8%. Hemopoietic toxicity was comparable in the two groups. Nausea and vomiting were much more severe in those patients receiving the four‐drug combination. Alopecia occurred in all patients on the four‐drug combination who received more than two courses of treatment.